ERBB2 and breast carcinoma: PI3KI alpelisib, AKT inhibitor capivasertib, and mTOR inhibitor everolimus are currently approved for hormone receptor-positive (HR) and human epidermal growth factor receptor 2-negative (HER2) breast cancer patients previously treated with endocrine therapy as further discussed below.